Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Infection Risk Amongst Patients Exposed to Biologic Medications
EF 2021-22
Résumé
Biologic medications are monoclonal antibodies that target cells, cytokines or receptors that have become paramount in the treatment of autoimmune and inflammatory conditions as rheumatologic diseases, dermatoses and malignancies. Many biologics exploit immunomodulatory properties to treat disease, that could unintentionally leave the host more vulnerable to infections.Studies investigating infections in patients receiving biologics have been highly restricted in looking only at a handful of specific drugs, used for only singular disease conditions. This process limits the generalizability of the findings and likely underestimates the infection risk of biologic drugs, particular as the number of applications grows.To better understand pathogen specific infectious risks, we will use the linked province-wide administrative health datasets at ICES to identify all infection diagnoses in patients receiving biologics using the international classification of disease (ICD-10) codes and via culture results from the Ontario Laboratory Information System. We will compare infection rates (overall and pathogen specific) to matched controls without exposure to biologics, as well as using self-controlled periods. Our analysis will be stratified by biologic drug and mechanism target, by underlying disease condition for which the biologic is prescribed, and by pathogen.The results of these analyses will advance our understanding of clinical immunobiology and will have important implications around patient counseling, the development of infection surveillance programs, antimicrobial prophylaxis, vaccination strategies, and will lend itself to potential future intervention studies aimed to reduce infections risks even further.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466777
Name
Parmar Parmvir
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Infection Risk Amongst Patients Exposed to Biologic Medications
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoimmune Disease; Biologics; Chronic Disease; Infections; Linked Administrative Database
Abstract
Biologic medications are monoclonal antibodies that target cells, cytokines or receptors that have become paramount in the treatment of autoimmune and inflammatory conditions as rheumatologic diseases, dermatoses and malignancies. Many biologics exploit immunomodulatory properties to treat disease, that could unintentionally leave the host more vulnerable to infections.Studies investigating infections in patients receiving biologics have been highly restricted in looking only at a handful of specific drugs, used for only singular disease conditions. This process limits the generalizability of the findings and likely underestimates the infection risk of biologic drugs, particular as the number of applications grows.To better understand pathogen specific infectious risks, we will use the linked province-wide administrative health datasets at ICES to identify all infection diagnoses in patients receiving biologics using the international classification of disease (ICD-10) codes and via culture results from the Ontario Laboratory Information System. We will compare infection rates (overall and pathogen specific) to matched controls without exposure to biologics, as well as using self-controlled periods. Our analysis will be stratified by biologic drug and mechanism target, by underlying disease condition for which the biologic is prescribed, and by pathogen.The results of these analyses will advance our understanding of clinical immunobiology and will have important implications around patient counseling, the development of infection surveillance programs, antimicrobial prophylaxis, vaccination strategies, and will lend itself to potential future intervention studies aimed to reduce infections risks even further.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Parmar, Parmvir
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~